Announcement
21 Dec 2021
On 21 December 2021, the EIB provided financing worth EUR 15 million (USD 17 million) to support Austrian company Innovacell's development of personalised cell therapies for the treatment of incontinence.
Source
Number of interventions
2
2 certainly harmful
0 likely harmful
0 liberalising
Implementation date
21 Dec 2021
Revocation date:
No revocation date
The EIB's EUR 15 million (approx. USD 17 million) loan with Innovacell signed on 21 December 2021 was backed by the European Guarantee Fund (EGF).
The EGF was created i...
On 21 December 2021, the European Investment Bank (EIB) and Austrian company Innovacell Ag signed an agreement worth EUR 15 million (approx. USD 17 million) to support Innovacell's development...
See all
This state act is not part of any Thread yet.